Track Revelation Biosciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Revelation Biosciences Inc. Common Stock REVB · Stock Open Revelation Biosciences Inc. Common Stock in new tab

4.27 USD
P/E
0.13
EPS
32.20
P/B
0.39
ROE
-133.36
Beta
-0.10
Loading chart...
Key Metrics
Earnings dateApril 1, 2027
P/E0.13
EPS32.20
Book Value10.58
Price to Book0.39
Debt/Equity11.13
% Insiders10.271%
Estimates
Forward P/E-0.25
Forward EPS-16.52

DCF valuation

Model fair value for Revelation Biosciences Inc. Common Stock (REVB)
Result
Sign in to run the valuation for REVB.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Revelation Biosciences Inc. Common Stock Logo Revelation Biosciences Inc. Common Stock Analysis (REVB)

United States Health Care Official Website Stock

Is Revelation Biosciences Inc. Common Stock a good investment? Revelation Biosciences Inc. Common Stock (REVB) is currently trading at 4.27 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.13. This relatively low multiple may signal that Revelation Biosciences Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Revelation Biosciences Inc. Common Stock is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -16.52.

Investor FAQ

Does Revelation Biosciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Revelation Biosciences Inc. Common Stock?

Revelation Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of 32.20.

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Exchange Ticker
NMS (United States) REVB
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Feb. 1, 2023 0.03
Jan. 25, 2024 0.03
Jan. 28, 2025 0.06
July 7, 2025 0.33
Jan. 28, 2026 1:4
Oct. 20, 2026 1:7
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion